Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347549 | 0.86 | HCAR2 (0.31) | — | |
| SCHEMBL702110 | 0.76 | CYP2A6 (0.59) | CYP2A6TBXAS1 | |
| SCHEMBL29438514 | 0.76 | CYP2A6 (0.59) | CYP2A6TBXAS1 | |
| SCHEMBL6195117 | 0.74 | HRH1 (0.50) | HIF1ATSHR | |
| SCHEMBL10651306 | 0.74 | — | — | |
| SCHEMBL5376031 | 0.71 | TDP1 (0.61) | CYP2A6TBXAS1 | |
| SCHEMBL8925031 | 0.70 | CYP11B1 (0.37) | CYP2A6TBXAS1 | |
| SCHEMBL29329263 | 0.70 | CYP2A6 (0.33) | CYP2A6 | |
| SCHEMBL12495594 | 0.70 | L3MBTL1 (0.50) | HIF1ATSHR | |
| SCHEMBL10423050 | 0.70 | CYP2A6 (0.57) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| CN-1183119-C | Arylpiperzines as metalloproteinase inhibiting agents (MMP) and their use | — | 2005-01-05 | — | — | CN | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-6734184-B1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| CN-1324347-A | Arylpiperzines as metalloproteinase inhibiting agents (MMP) and their use | ASTRA ZENECA LTD (SE) | 2001-11-28 | — | — | CN | disclosed |
| EP-1109787-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012478-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | HIF1A 1119/4885TSHR 2604/4885CYP2A6 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.